For the 4th of February - World Cancer Day 2018
In the biennial mammography screening programme, the most frequent diagnosis of breast cancer in its preliminary stages is, biologically, the most aggressive form. High-grade ductal carcinoma in situ holds the greatest risk of developing into a so-called invasive carcinoma. The tumour in question is malignant and grows into the surrounding tissue, and can spread into the lymphatic nodes and other organs.
In the latest screening programme carried out in North Rhine-Westphalia, data were evaluated pertaining to around 714,000 women who had regularly taken part in the programme up to three times, with a two-year interval between each screening. Breast cancer at a preliminary stage was discovered in 1,970 women, and in half of these cases it was present in its most aggressive form in the follow-up screening.
The results indicate that there might be far fewer overdiagnoses in mammography screening than has been discussed so far. Overdiagnoses are cases of breast cancer that have been discovered which would not have become apparent during the lifetime of a woman who had not undergone any screening. The greatest probability of an overdiagnosis being made is ascribed to the “harmless” preliminary stages of breast cancer which can develop into invasive breast cancer only more than ten years later.
On the basis of a large quantity of data, the interdisciplinary team of researchers at the University of Münster has shown that most of the preliminary stages of breast cancer discovered in subsequent rounds of screening are aggressive and that their development is far more quickly than of the more harmless forms. Therefore, as a percentage they increase in repeated screenings. This means, conversely, that it is above all women who regular take part in mammography screening who benefit in particular. The reason is that if the preliminary stages of the breast cancer are aggressive, they are often discovered as a result of this form of early detection before they can develop into invasive, aggressive breast cancer.